The publication is a positive clinical data point but does not alter the commercial trajectory already set by the FDA label expansion. Monitor upcoming quarterly earnings for EMPAVELI sales growth and any competitive pipeline developments in C3G/IC-MPGN.
Price Chart
Executive Summary
Biogen published positive adolescent subgroup results from the Phase 3 VALIANT study of EMPAVELI in C3G and primary IC-MPGN, showing a 75% relative reduction in proteinuria vs placebo. The publication follows a recent FDA label expansion for adolescents, reinforcing the drug's clinical profile in a rare kidney disease population. This is a supportive data readout for an already-approved indication, not a new catalyst.
Key Facts
- EMPAVELI-treated adolescents achieved a 75% relative reduction in proteinuria vs placebo (95% CI: 59%-84%; nominal p<0.001) at Week 26.
- 71% of adolescents on EMPAVELI achieved ≥50% reduction in proteinuria vs 4% on placebo (nominal p<0.001).
- 57% of EMPAVELI-treated adolescents achieved both stable kidney function and ≥50% proteinuria reduction vs 4% on placebo (nominal p=0.002).
- Results published in the Clinical Journal of the American Society of Nephrology (CJASN).
- FDA recently expanded EMPAVELI's label to include reducing loss of kidney function in patients 12 years and older, in addition to reducing proteinuria.
- EMPAVELI is the only approved treatment for adolescents with C3G and primary IC-MPGN.
Financial Impact
No financial figures provided in the press release. EMPAVELI is already approved and generating revenue; this publication supports the label expansion but does not change the addressable market or pricing.
Risk Factors
- EMPAVELI carries a boxed warning for serious infections from encapsulated bacteria, which may limit adoption.
- C3G and primary IC-MPGN are ultra-rare diseases with small patient populations, capping peak revenue potential.
- Competing complement inhibitors in development could erode EMPAVELI's first-mover advantage.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3364391 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 8d ago | Press Release | $233.48 | awaiting T+60 | — | $252.21 (+8.02%) |
Oct 12, 2026 15d ago | ANALYST-UPGRADE | $229.41 | awaiting T+60 | — | $252.21 (+9.94%) |
Oct 2, 2026 25d ago | Press Release | $219.88 | awaiting T+60 | — | $252.21 (+14.71%) |
Sep 17, 2026 5w ago | Press Release | $215.50 | awaiting T+60 | — | $252.21 (+17.04%) |
Sep 3, 2026 7w ago | Press Release | $220.83 | awaiting T+60 | — | $252.21 (+14.21%) |
Sep 3, 2026 7w ago | Press Release | $224.51 | awaiting T+60 | — | $252.21 (+12.34%) |
Aug 6, 2026 11w ago | Press Release | $207.94 | awaiting T+60 | — | $252.21 (+21.29%) |
Jul 14, 2026 15w ago | Press Release | $191.95 $222.15 | ▲ +15.73% | ▲ +12.36% | $252.21 (+31.40%) |
Jul 13, 2026 15w ago | Press Release | $191.95 $222.15 | ▲ +15.73% | ▲ +12.36% | $252.21 (+31.40%) |
Jul 13, 2026 15w ago | ANALYST-UPGRADE | — | awaiting T+60 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers